Cerebrolysin Research for Alzheimer's Disease
An evidence-based overview of research examining Cerebrolysin in the context of alzheimer's disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
Multiple Phase 3 trials and meta-analyses support cerebrolysin for mild-moderate Alzheimer's disease. A meta-analysis of 6 RCTs (N=784) showed OR 3.32 for clinical improvement, comparable to cholinesterase inhibitors. Effects include improved ADAS-cog scores that persist 3 months post-treatment.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Alzheimer's Disease
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cerebrolysin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.